Dexcom Inc
Change company Symbol lookup
Select an option...
DXCM Dexcom Inc
$ICEFSTS ICE FactSet Taiwan Core Semiconducto
UGRO Urban-Gro Inc
NVVEW Nuvve Holding Equity Warrants Exp 19 March 2026 *W EXP 03/19/2026
AGNCN AGNC Investment Corp
XJMMX Nuveen Multi-Market Income Fund Inc
THDDY TV Asahi Holdings Corp
ABCB Ameris Bancorp
NSAUF MegumaGold Corp
TSIBW Tishman Speyer Innovation Equity II Warrant Exp 11 Feb 2026 *W EXP 02/11/2026

Health Care : Health Care Equipment & Supplies | Large Cap Growth
Company profile

Dexcom, Inc. is a medical device company. The Company is primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for use by people with diabetes and by healthcare providers. Its products include Dexcom G6 and Dexcom Share. The G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an app on the patient’s iPhone, iPod touch, iPad or Android mobile device to securely and wirelessly transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients, who can remotely monitor a patient’s glucose information and receive alert notifications.

Closing Price
Day's Change
4.73 (1.12%)
B/A Size
Day's High
Day's Low
(Above Average)

10-day average volume:



6 providers
Yesterday's News, January 24, 2022
Dexcom Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 10, 2022 at 4:30 p.m. Eastern Time.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Thursday, February 10, 2022. Management will hold a conference call to review the company's fourth...(BusinessWire)

January 10, 2022
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter 2021 and Summary Data from the Dexcom G7 U.S. Pivotal Trial

DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring ("CGM"), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2021 to be approximately $698 million, an increase of...(BusinessWire)

January 04, 2022
Dexcom to Present at 40th Annual J.P. Morgan Healthcare Conference

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 40th annual J.P. Morgan Healthcare Conference on January 10, 2022. (BusinessWire)

November 29, 2021
Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference: Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the...(BusinessWire)

November 01, 2021
Dexcom, Nick Jonas, Patti LaBelle and The Global Movement for Time in Range Invite the World to #SeeDiabetes This November

Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, its nonprofit partners and members of the diabetes community are banding together to help people with diabetes feel more seen and heard...(BusinessWire)

October 28, 2021
Dexcom Reports Third Quarter 2021 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2021. Third Quarter 2021 Financial Highlights: Revenue grew 30% versus the same quarter of the prior year to $650.2 million on a reported...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.